Faron Pharma Share News (FARN)

Faron Pharmaceuticals test data shows efficacy of bexmarilimab

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy and safety of the immunotherapy in solid tumours.

TRADING UPDATES: Anglo Asian gold output down; Faron hails antibody

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharma names James O'Brien, once of Bristol-Myers, as new CFO

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said it has appointed James O'Brien as its new chief financial officer, effective from Monday next week, succeeding Toni Hanninen.

Faron Pharmaceuticals names James O'Brien as CFO

(Sharecast News) - Drug discovery and development company Faron Pharmaceuticals has tapped James O'Brien to take over as its new chief financial officer.

Faron Pharmaceuticals gets positive feedback from FDA meeting

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals said on Wednesday that it had received positive feedback from the US Food and Drug Administration (FDA) on the development of its precision immunotherapy asset 'bexmarilimab'.

UK shareholder meetings calendar - next 7 days

Faron Pharmaceuticals annual loss widens on higher research costs

(Alliance News) - Faron Pharmaceuticals Ltd on Friday reported a widened loss in 2022 as it ramped up its research & development efforts.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Faron Pharmaceuticals raises EUR12 million via shares

Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical drug discovery and development company - Raises EUR12.0 million via placing of 3.7 million shares at the issue price of EUR3.25 each. Faron says that with these proceeds and the current level of activity, it has sufficient working capital into the third quarter of 2023.

AIM WINNERS & LOSERS: Faron Pharmaceuticals raises EUR12 million

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

TRADING UPDATES: Tungsten West 'largest Western tungsten producer'

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharmaceuticals sees patient remission in immunotherapy trials

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it was encouraged by promising early data from trials for its investigative precision immunotherapy, which aims to provide permanent immune stimulation for difficult-to-treat cancers by targeting myeloid cell function.

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: